tiprankstipranks
Trending News
More News >
GNI Group Ltd. (DE:3G6)
FRANKFURT:3G6
Advertisement

GNI Group (3G6) Price & Analysis

Compare
0 Followers

3G6 Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.45%97.20%
Insiders
0.45%
Mutual Funds
― Other Institutional Investors
97.20% Public Companies and
Individual Investors

3G6 FAQ

What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €8.80 and its highest was €26.00 in the past 12 months.
    What is GNI Group Ltd.’s market cap?
    GNI Group Ltd.’s market cap is €914.36M.
      When is GNI Group Ltd.’s upcoming earnings report date?
      GNI Group Ltd.’s upcoming earnings report date is Aug 14, 2025 which is in 30 days.
        How were GNI Group Ltd.’s earnings last quarter?
        Currently, no data Available
        Is GNI Group Ltd. overvalued?
        According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GNI Group Ltd. pay dividends?
          GNI Group Ltd. does not currently pay dividends.
          What is GNI Group Ltd.’s EPS estimate?
          GNI Group Ltd.’s EPS estimate is 0.77.
            How many shares outstanding does GNI Group Ltd. have?
            GNI Group Ltd. has 50,538,445 shares outstanding.
              What happened to GNI Group Ltd.’s price movement after its last earnings report?
              Currently, no data Available
              Which hedge fund is a major shareholder of GNI Group Ltd.?
              Currently, no hedge funds are holding shares in DE:3G6

              Company Description

              GNI Group Ltd.

              GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
              Similar Stocks
              Company
              Price & Change
              Follow
              Peptidream
              SanBio Co
              Sosei Group
              Healios KK
              Takara Bio Inc.
              Popular Stocks
              What am I Missing?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis